A comparison trial of Gallium-68-DOTATOC and Indium-111-pentetreotide in patients with MEN1 duodenal and pancreatic neuroendocrine tumors.
Phase of Trial: Phase IV
Latest Information Update: 22 Jun 2016
At a glance
- Drugs Gallium 68-DOTATOC (Primary) ; Indium-111-pentetreotide (Primary)
- Indications Duodenal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Diagnostic use
- 22 Jun 2016 New trial record